Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14337995 | 0.90 | CYP3A4 (0.30) | CYP3A4ALOX15 | |
| SCHEMBL14337993 | 0.90 | CYP3A4 (0.33) | CYP3A4ALOX15POLB | |
| SCHEMBL5385435 | 0.87 | POLB (0.38) | CYP3A4ALOX15POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL5385291 | 0.87 | CYP3A4 (0.41) | CYP3A4ALOX15POLBACHEALDH1A1 | |
| SCHEMBL14337998 | 0.87 | RAB9A (0.30) | RAB9A | |
| SCHEMBL14337872 | 0.85 | CYP3A4 (0.39) | CYP3A4ALOX15POLBACHEALDH1A1 | |
| SCHEMBL14337939 | 0.85 | CYP3A4 (0.39) | CYP3A4ALOX15POLBACHEALDH1A1 | |
| SCHEMBL14350686 | 0.84 | POLB (0.40) | CYP3A4ALOX15POLBACHEALDH1A1 | |
| SCHEMBL5383846 | 0.84 | CYP3A4 (0.37) | CYP3A4ALOX15POLBACHE | |
| SCHEMBL5385283 | 0.84 | POLB (0.37) | CYP3A4ALOX15POLBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312347-B2 | Substituted optically active disphosphine compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| US-7312347-B2 | Substituted optically active disphosphine compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| US-7312347-B2 | Substituted optically active disphosphine compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| US-20070073065-A1 | Substituted optically active disphosphine compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070073065-A1 | Substituted optically active disphosphine compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070073065-A1 | Substituted optically active disphosphine compound | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070073065-A1 | Substituted optically active disphosphine compound | DHPS, DOHH, DHODH | CYP3A4 374/4885ALOX15 1783/4885POLB 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.